Table 1.

Laboratory data from first and second successful pregnancy.

Time	Hb, mg/dl	WBC, per cm²	Platelet Count, k/cm²	Serum Creatinine, mg/dl	UPCR, mg/mg	C3, 88–201 mg/dl	C4, 16–47 mg/dl	dsDNA Titer
3 mos before belimumab	11.9	8.2	215	1.12	0.11	62	8	1:80
At initiation of belimumab	11.8	4.0	176	0.89	0.1	73	17	1:40
6 mos after belimumab	11.8	2.6	170	0.77	0.14	73	22	—
12 mos after belimumab	12	2.1	140	0.83	0.25	59	16	—
First trimester, first pregnancy	11.7	1.9	161	0.59	0.14	87	24	1:40
Second trimester, first pregnancy	10.8	1.5	164	0.78	0.28	98	35	1:80
Third trimester, first pregnancy	10.9	2.4	158	0.70	0.19	99	32	1:40
Postpartum, first pregnancy	11.9	0.9	195	0.78	—	73	22	1:80
3 mos before second pregnancy	12.1	1.37	274	0.79	0.12	122	36	1:80
First trimester, ∼8 weeks	13.0	1.58	246	0.78	—	—	—	—
Second trimester, ∼20 weeks	10.7	1.84	205	0.64	0.15	140	46	—
Third trimester, ∼34 weeks	12.0	1.46	175	0.73	0.16	—	—	—
3 weeks postpartum, first belimumab infusion postpartum	12.5	1.74	301	0.75	0.16	—	—	—
6 mos postpartum	12.4	0.97	213	0.68	0.22	140	30	48 (quantitative)
12 mos postpartum	12.9	1.15	203	0.72	—	—	—	—